化疗难治性局限性炎性乳腺癌的术前放射治疗
这项回顾性多中心队列研究纳入2010至2017年法国7家肿瘤中心的364例炎性乳腺癌患者,其中18例(5%)在新辅助化疗期间出现疾病进展。这些化疗难治性患者接受术前放射治疗后,全部达到完全或部分局部区域缓解,12例(66.7%)按计划接受手术,但中位总生存仅19个月,13例(72.2%)出现转移进展。
要点
- 化疗难治性非转移性炎性乳腺癌占全部炎性乳腺癌的5%(18/364)。
- 术前放疗后全部患者达到完全(5.6%)或部分(94.4%)局部区域缓解,1例(5.6%)出现急性3级皮炎。
- 三阴性亚型与总生存显著相关(单因素HR 15.54,P=.011;多因素HR 13.04,P=.021)。
核心结论
- 术前放射治疗是可行的方法,毒性可接受,使多数患者得以手术并获得最终局部区域控制,但未转化为生存获益,部分归因于化疗难治性炎性乳腺癌的转移倾向,尤其是本系列中占比过高的三阴性人群。
研究设计与样本
- 回顾性多中心队列研究,纳入2010至2017年法国7家肿瘤中心连续诊断的炎性乳腺癌患者364例,其中化疗难治性疾病(新辅助化疗期间局部区域进展)接受术前放射治疗者18例(5%)。
主要发现
- 18例化疗难治性患者中,诊断时淋巴结受累17例(94.4%),三阴性亚型11例(61.1%),Scarff Bloom and Richardson 3级10例(55.6%),Ki67中位数56.0%。
- 术前放射治疗后,全部患者达到完全(1例,5.6%)或部分(17例,94.4%)局部区域缓解,1例(5.6%)出现急性3级皮炎,12例(66.7%)按计划接受手术。
- 估计中位随访31个月,中位总生存19个月,无病生存4.5个月,无远处转移生存5个月,无局部区域复发生存6个月。
- 最终局部区域控制11例(61.1%),13例(72.2%)出现转移进展。
- 单因素分析中,三阴性亚型(HR 15.54,P=.011)和手术(HR 0.23,P=.030)与总生存显著相关;多因素分析中三阴性亚型仍是总生存的显著预后因素(HR 13.04,P=.021)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Inflammatory breast cancer (IBC) is a rare breast cancer subtype. Chemorefractory nonmetastatic IBC, defined by locoregional progression under neoadjuvant chemotherapy, is a rare situation with few therapeutic options. Owing to the rarity of this clinical presentation and the lack of specific data, no specific management guidelines exist. We evaluated whether preoperative radiation therapy/chemoradiotherapy could achieve locoregional control after first-line neoadjuvant chemotherapy in patients with IBC. METHODS AND MATERIALS: Patients with chemorefractory disease receiving preoperative radiation therapy were identified from a retrospective multicenter cohort of consecutive patients with IBC diagnosed between 2010 and 2017 at 7 oncology centers in France. RESULTS: Overall, 18 patients among the 364 patients (5%) treated for IBC had progressive disease during neoadjuvant chemotherapy. These patients had aggressive tumors with lymph node involvement at diagnosis (n = 17; 94.4%), triple-negative subtype (n = 11; 61.1%), Scarff Bloom and Richardson grade 3 (n = 10; 55.6%), and high Ki67 (median, 56.0%). After preoperative radiation therapy, all patients had a complete (n = 1; 5.6%) or partial (n = 17; 94.4%) locoregional response. One patient (5.6%) experienced acute grade 3 dermatitis. Twelve (66.7%) patients underwent surgery as planned. The estimated median follow-up was 31 months. The median overall survival, disease-free survival, distant metastases-free survival, and locoregional recurrence-free survival were 19 months, 4.5 months, 5 months, and 6 months, respectively. Ultimate locoregional control was obtained for 11 patients (61.1%), and 13 patients (72.2%) experienced metastatic progression. Triple-negative subtype (hazard ratio [HR], 15.54; P = .011) and surgery (HR, 0.23; P = .030) were significantly associated with overall survival in the univariate analysis. In multivariate analyses, the triple-negative subtype remained a significant prognostic factor (HR, 13.04; P = .021) for overall survival. CONCLUSIONS: Preoperative radiation therapy is a feasible approach with acceptable toxicities. It allowed surgery and ultimate locoregional control in a majority of patients. The lack of translation into better survival has been a challenge, in part owing to the metastatic propensity of patients with chemorefractory IBC, especially in the overrepresented triple-negative population in this series.
引用
- Rogé M, Kirova Y, Loap P, et al. Preoperative Radiation Therapy for Chemorefractory Localized Inflammatory Breast Cancer. Pract Radiat Oncol. 2023. PMID: 37295726. doi:10.1016/j.prro.2023.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。